Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 12/20 | 0.40 |
| ▸ | CTSS | P25774 | 9/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27567084 | 0.83 | CTSK (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL27668563 | 0.83 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL27593364 | 0.83 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL6206893 | 0.83 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL27567001 | 0.83 | CTSK (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL6684772 | 0.77 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL9690240 | 0.76 | CA1 (0.40) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL14984731 | 0.76 | CTSK (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL168105 | 0.76 | CTSK (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL28407843 | 0.75 | CYP2D6 (0.50) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172422-A1 | Methods of Treatment Using a Prodrug of an Excitatory Amino Acid | ELI LILLY AND COMPANY (US) | 2012-07-05 | — | — | US | disclosed |
| US-8153683-B2 | Methods of treatment using a prodrug of an excitatory amino acid | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110207672-A1 | METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-7964632-B2 | Methods of treatment using a prodrug of an excitatory amino acid | ELI LILLY AND COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100113579-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2010-05-06 | — | — | US | disclosed |
| US-7671082-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080182889-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | MOHER ERIC DAVID | 2008-07-31 | — | — | US | disclosed |
| US-7371872-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1897550-A2 | Prodrugs of Excitatory Amino Acids | Eli Lilly & Company (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20050222231-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | US | disclosed |
| EP-1517915-A2 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003104217-A2 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172422-A1 | Methods of Treatment Using a Prodrug of an Excitatory Amino Acid | SLC1A2, SLC1A1, SLC1A3 | CA1 206/4885CA2 1068/4885CA7 2409/4885 |
| US-20100113579-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | SLC1A2, SLC1A1, SLC1A3 | CA1 212/4885CA2 1274/4885CA7 3165/4885 |
| US-20110207672-A1 | METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID | SLC1A2, SLC1A1, SLC1A3 | CA1 206/4885CA2 1068/4885CA7 2409/4885 |
| US-20050222231-A1 | Prodrugs of excitatory amino acids | SLC1A2, SLC1A1, SLC1A3 | CA1 212/4885CA2 1274/4885CA7 3165/4885 |
| US-20080182889-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | SLC1A2, SLC1A1, SLC1A3 | CA1 212/4885CA2 1274/4885CA7 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.